Trial Profile
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 17 Jan 2021 Primary endpoint of Number of patients who complete pre-op treatment and proceed to surgery has been met, according to results presented at the 2021 Gastrointestinal Cancers Symposium.
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium